These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33616313)

  • 41. Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
    Vanhuyse M; Penel N; Caty A; Fumagalli I; Alt M; Zini L; Adenis A
    Bull Cancer; 2012 Dec; 99(12):100-6. PubMed ID: 23220100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trials probe new agents for kidney cancer.
    Hampton T
    JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
    [No Abstract]   [Full Text] [Related]  

  • 43. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Gschwend J; Keilholz U
    Aktuelle Urol; 2011 Jul; 42(4):242-6. PubMed ID: 21720974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deal watch: Aveo and Astellas to develop VEGF inhibitor for renal cell carcinoma.
    Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455225
    [No Abstract]   [Full Text] [Related]  

  • 45. [Renal cell carcinoma management and therapies in 2010].
    Albouy B; Gross Goupil M; Escudier B; Massard C
    Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reply to T.G. Karrison.
    Nosov DA; Strahs AL
    J Clin Oncol; 2013 Feb; 31(6):814-5. PubMed ID: 23544201
    [No Abstract]   [Full Text] [Related]  

  • 47. [Advanced renal carcinomas with special situations. How to treat them?].
    Pouessel D; Patard JJ; Culine S
    Bull Cancer; 2010; 97():83-90. PubMed ID: 20418207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
    Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
    Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
    P J G; A M; L M; H J H; M K; S B; N M
    Urol Oncol; 2014 Apr; 32(3):362-70. PubMed ID: 24321255
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 52. Prognostic factors in patients treated with VEGF-targeted therapies.
    Choueiri TK
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):92-3. PubMed ID: 20386528
    [No Abstract]   [Full Text] [Related]  

  • 53. Estimation of progression-free survival in the randomized discontinuation trial design.
    Karrison TG
    J Clin Oncol; 2013 Feb; 31(6):814. PubMed ID: 23319693
    [No Abstract]   [Full Text] [Related]  

  • 54. Bevacizumab and everolimus in renal cancer: a rational way forward.
    Stadler WM; Phillips G; George DJ; Halabi S; Small E
    J Clin Oncol; 2010 Nov; 28(33):e692-3; author reply e694. PubMed ID: 20940194
    [No Abstract]   [Full Text] [Related]  

  • 55. [Not Available].
    Borchiellini D
    Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
    Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
    Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
    Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
    Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
    Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.